View Older Stories View More Recent Stories

Nov 10, 2021 04:05PM KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
Nov 5, 2021 07:30AM KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
Nov 3, 2021 09:22AM KemPharm to Report Third Quarter 2021 Results
Oct 27, 2021 07:30AM AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
Oct 20, 2021 07:30AM KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)
Oct 19, 2021 07:30AM KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
Sep 27, 2021 07:30AM KemPharm to Present at the Benzinga Healthcare Small Cap Conference
Sep 23, 2021 07:30AM KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 9, 2021 07:30AM KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
Aug 18, 2021 04:45PM KemPharm (KMPH) Appoints Tamara A. Seymour to its Board
Aug 18, 2021 04:45PM KemPharm Appoints Tamara A. Seymour to Board of Directors
Aug 12, 2021 04:05PM KemPharm Reports Second Quarter 2021 Financial Results
Aug 5, 2021 07:30AM KemPharm to Report Second Quarter 2021 Results
Jul 21, 2021 08:31AM KemPharm (KMPH) Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
Jul 21, 2021 08:30AM KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
Jun 16, 2021 07:32AM KemPharm (KMPH) Issues Letter to Shareholders
Jun 16, 2021 07:30AM KemPharm Issues Letter to Shareholders
Jun 9, 2021 07:30AM KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
Jun 3, 2021 07:30AM KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences
May 26, 2021 07:30AM KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
May 13, 2021 04:05PM KemPharm Reports First Quarter 2021 Financial Results
May 7, 2021 07:34AM KemPharm (KMPH) Announces Serdexmethylphenidate Has Been Classified as Schedule IV Controlled Substance by the DEA
May 7, 2021 07:30AM KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
May 6, 2021 04:30PM KemPharm to Report First Quarter 2021 Results
Apr 21, 2021 04:45PM KemPharm (KMPH) Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS Per License Agreement with Affiliate of Gurnet Point Capital
Apr 21, 2021 04:45PM KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital
Apr 8, 2021 04:08PM KemPharm (KMPH) Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS
Apr 8, 2021 04:05PM KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™
Mar 11, 2021 04:25PM KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
Mar 9, 2021 07:30AM KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results
Mar 4, 2021 04:41PM KemPharm to Present at the 33rd Annual Roth Conference
Mar 3, 2021 06:05AM KemPharm (KMPH) Announces FDA Approval of AZSTARYS, A New Once-Daily Treatment for ADHD
Mar 2, 2021 11:31PM KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Jan 27, 2021 08:34AM KemPharm (KMPH) Granted FDA Clearance to Initiate KP879 Clinical Program for Treatment of Stimulant Use Disorder
Jan 27, 2021 08:30AM KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
Jan 14, 2021 07:30AM KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
Jan 13, 2021 07:30AM KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
Jan 8, 2021 08:35AM KemPharm (KMPH) Prices 7.69M Share Common and Warrant Offering at $6.50/Sh
Jan 8, 2021 08:30AM KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
Dec 23, 2020 06:11PM KemPharm Announces 1-for-16 Reverse Stock Split
Dec 22, 2020 07:30AM KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
Dec 2, 2020 07:30AM KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
Nov 30, 2020 07:30AM REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
Nov 23, 2020 04:30PM KemPharm Provides Update on Development Pipeline
Nov 18, 2020 08:30AM KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
Oct 29, 2020 04:05PM KemPharm Reports Third Quarter 2020 Financial Results
Oct 26, 2020 08:30AM KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
Oct 22, 2020 07:30AM KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
Oct 5, 2020 08:46AM KemPharm and Corium Expand Relationship with New Consultation Services Agreement
Sep 25, 2020 05:00PM KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
View More Recent Stories View Older Stories